Hyperfine, Inc. (HYPR) encountered a quarterly loss of $0.15 per share, slightly better than the estimated loss of $0.17, and an improvement from the year-ago loss of $0.19. These numbers are tailored for one-time occurrences.
This quarterly revelation is an earnings surprise of 11.76%. Last quarter, the expected loss was $0.15 per share, aligning perfectly with the delivered loss.
In the past year, the company outperformed consensus EPS predictions twice.
Hyperfine finds its place in the Zacks Medical – Instruments industry, generating $2.69 million in revenue for the fourth quarter of December 2023, a significant 26.61% below the Zacks Consensus Estimate. This marks an increase from the previous year’s $1.42 million. The business has outperformed consensus revenue expectations twice in the last four quarters.
The stock’s near future trajectory rests on the management’s insights during the earnings call, aligning with the company’s recently released figures and future earnings prospects.
Since the start of the year, Hyperfine shares have seen a modest 2.7% rise, falling behind the S&P 500’s 9.5% increase.
Forecasting Hyperfine’s Trajectory
Despite Hyperfine’s underwhelming stock performance this year, investors wonder about the company’s future direction.
Determining the stock’s future remains a conundrum. However, a dependable measure to gauge its potential is the company’s earnings outlook, encompassing current consensus earnings for upcoming quarters and recent changes in forecasts.
Research suggests a strong correlation between short-term stock movements and patterns in earnings estimate adjustments. Investors can track these revisions independently or rely on established tools like the Zacks Rank, known for leveraging the power of earnings revisions.
Prior to this earnings declaration, Hyperfine’s estimate revision trend remains mixed. Despite potential shifts following the latest earnings report, the present status assigns a Zacks Rank #3 (Hold) to the stock, forecasting performance in line with the market shortly. Refer to the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Observing how estimates for future quarters and the current fiscal year evolve in the coming days proves intriguing. Presently, the consensus EPS estimate stands at -$0.15 for the upcoming quarter with revenues totaling $4.1 million, and -$0.62 for the current fiscal year on $18.28 million in revenues.
It’s essential for investors to recognize that industry forecasts can significantly influence stock performance. Currently, the Medical – Instruments segment ranks in the top 28% of over 250 Zacks industries. Studies show that the top 50% of Zacks-ranked industries outperform the bottom 50% by over a 2 to 1 margin.
Another industry player, Intuitive Surgical, Inc. (ISRG), is yet to announce its results for the quarter concluding March 2024.
The company is projected to unveil quarterly earnings of $1.39 per share in its imminent report, reflecting a 13% year-over-year rise. Consensus EPS estimates for the quarter have remained constant over the past month.
Revenues for Intuitive Surgical, Inc. are anticipated to hit $1.87 billion, a 10.1% boost from the corresponding period last year.
5 Stocks Set to Double
Each picked by Zacks experts as the top stock to gain over 100% in 2024. Previous suggestions have seen increments of +143.0%, +175.9%, +498.3%, and +673.0%.
Most stocks in this report are flying under Wall Street’s radar, offering an excellent opportunity to enter at the initial stages.
Today, See These 5 Potential Home Runs >>
Looking for the latest advice from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days today. Click here to get this free report
Hyperfine, Inc. (HYPR) : Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein represent those of the author and not necessarily Nasdaq, Inc.
